Wake Forest University Health Sciences

Compiled by PlainTrial · August 8, 2026

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).

1,140 total trials 174 currently recruiting 724 completed early-phase tilt top decile by trial count

Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.

Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.

Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,140 total, page 3 of 23

Wake Forest University Health Sciences

Top-decile sponsor footprint

Open and recent trials

Reducing Risk for Infective Endocarditis

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Reducing Tobacco Smoking: a Transcranial Direct Current Stimulation (TDCS) Telehealth Study

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Take A Break - Rural

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

Identifying Challenges to Healthy Aging in Persons With Human Immunodeficiency Virus (HIV) Age 50 and Older

REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss

Bone, Exercise, Alendronate, and Caloric Restriction

Repurposing Low-Dose Clonidine for PTSD in Veterans

Implantation Of Vaginal Construct For Patients With Vaginal Aplasia

Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

Collaborative Care for Anxiety and Depression in Epilepsy

Collaborative Care in Posttraumatic Epilepsy

Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2

NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks

Cardiovascular Effects of Very Low Nicotine Content Cigarettes

Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery

Total Intravenous Anesthesia (TIVA)/Sevoflurane Initiated Intravenous Anesthesia (SIIVA) in Pediatric Patients

Improving Exercise Capacity With a Tailored Physical Activity Intervention

Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction

Coconut Oil to Prevent Mouth Sores in Pediatric Patients Receiving High Dose Chemotherapy

Autologous Muscle Fiber Fragment Injections

Physical Therapy Wound Care Modalities in Patients With Spinal Cord Injury (SCI)

MRI in High-Grade Glioma Patients Undergoing Chemoradiation

Investigation of PEMF Therapy for Female Patients With IC/BPS

Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients

Randomized Control Trial, Cryoablation as an Adjunct to Surgical Stabilization of Rib Fractures

Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma

Cereset Research for Caregivers

NextGen - Clinical Implication of Next Generation Sequencing

Appalachian Partnership to Reduce Disparities (Aim 2)

Oral Aromatase Inhibitors Modify the Gut Microbiome

Conversations You Want About Corona Virus Disease (COVID-19)

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

Xeomin® and Gait Related Mobility After Stroke

Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives

Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury

Dyad Plus Effectiveness/Feasibility

A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

An Internet-based Program to Help Cancer Survivors Manage Pain

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy

Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity

Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm

Phase Distribution

Therapeutic Areas

What is open in the Wake Forest University Health Sciences pipeline

Wake Forest University Health Sciences: open-pipeline peers nationwide

Sponsors near 1,140 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

Related